| Document |
Document Title |
|
WO/2022/251359A1 |
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
|
|
WO/2022/249942A1 |
The present invention addresses the problem of providing a protective agent for neurons of the retina exemplified by retinal ganglion cells and retinal photoreceptor cells. As a means for solving the problem, this protective agent for ne...
|
|
WO/2022/251370A1 |
The invention relates to methods of treating certain retinal vasculopathies such as diabetic macular edema, diabetic retinopathy and dry and neovascular age-related macular degeneration, among others. In some instances, the method includ...
|
|
WO/2022/249069A1 |
A topical ophthalmological formulation comprises carbachol at a low concentration that effects reduction in pupil diameter over time when repeatedly administered over at least a week. Such formulations are particularly beneficial where c...
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
|
WO/2022/248634A1 |
The present invention concerns a new gene therapy approach to increase light-sensitivity in degenerating cones in advanced stages of rod-cone dystrophy (RCD) mediated by G-protein-gated-K+ channel (GIRK), in particular GIRK1 F137S, activ...
|
|
WO/2022/244765A1 |
[Problem] To provide a novel eye drop for suppressing myopia. [Solution] The above problem has been solved by using an eye drop containing bunazosin as an eye drop for suppressing myopia. This eye drop for suppressing myopia is effective...
|
|
WO/2022/245950A1 |
Disclosed herein are methods for the treatment of Demodex including the step of contacting the Demodex with 5-fluorouracil, or salt thereof. Disclosed herein are ophthalmic compositions including 5-fluorouracil or salt thereof suitable f...
|
|
WO/2022/245919A1 |
Provided herein are recombinant AAV vectors, AAV viral vectors, capsid proteins, and administration methods for improved gene therapy, and methods for their manufacture and use.
|
|
WO/2022/242695A1 |
The present invention relates to a composition, a preparation method therefor, and a use thereof. The composition comprises a PEDF-derived short peptide (PDSP), a stabilizer, and a buffer agent. The pH of the composition ranges from 4 to...
|
|
WO/2022/244757A1 |
The present invention provides a pharmaceutical composition for treating or preventing a disorder associated with administration of an anticancer agent. The present invention relates to a pharmaceutical composition for treating or preven...
|
|
WO/2022/246280A1 |
A composition comprising nanoparticles having a molecule that is a cell targeting or cell penetrating molecule and an anti-oxidant, and methods of making and using the composition, are provided.
|
|
WO/2022/245739A1 |
The present invention relates to treatment regimens characterized by high doses of aflibercept (e.g., 8 mg) and extended intervals between doses (e.g., 12 weeks) with improved visual and anatomic outcomes relative to treatment with lower...
|
|
WO/2022/242766A1 |
The present invention relates to a method for modulating neuropathies. The method comprises: administering to a subject a therapeutically effective amount of doxazosin, a pharmaceutically acceptable salt or an acceptable form thereof, a ...
|
|
WO/2022/237178A1 |
The present invention relates to a bicyclic heteroaryl derivative and a preparation method therefor and a use thereof in medicine. Specifically, the present invention relates to a bicyclic heteroaryl derivative represented by formula (AI...
|
|
WO/2022/238327A1 |
The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compound...
|
|
WO/2022/238335A1 |
The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for...
|
|
WO/2022/241456A1 |
Described herein are methods for reducing or preventing intraocular pressure in a subject. The methods involve administering to the subject a delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibito...
|
|
WO/2022/238251A2 |
The present invention is related to a preservative free ophthalmic low concentration atropine sulfate composition containing atropine sulfate in an amount from about 0.005 w/w% to about 0.05 w/w%, a tonicity agent, water and a pH adjuste...
|
|
WO/2022/159677A9 |
The present disclosure provides compositions and methods for treating eye diseases ( e.g., retinopathies), and more particularly, eye diseases associated with cytotoxic lipofuscin- associated cytotoxicity in retinal cells.
|
|
WO/2022/240165A1 |
The present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration. Age-related macular degeneration is the number one cause of adult blindness in developed countries. Dry age-relate...
|
|
WO/2022/241465A1 |
The present disclosure relates to pharmaceutical compositions comprising a growth factor and methods of treating or preventing of eye diseases using the growth factor and compositions thereof.
|
|
WO/2022/240598A1 |
Chondroitin sulfate-based pharmaceutical formulations useful for the treatment of ocular pain or discomfort, such as occurring from ocular surgery, dry eye disease, ocular surgery induced dry eye disease, contact lens induced ocular surf...
|
|
WO/2022/238250A1 |
The present invention is related to a preservative free ophthalmic low concentration atropine sulfate composition containing atropine sulfate in an amount from about 0.005 w/w% to about 0.05 w/w%, citrate buffer, a tonicity agent and wat...
|
|
WO/2022/238833A1 |
The present invention relates to a composition for oral use in the form of aqueous solution comprising citicoline and nicotinamide and said composition for use in the treatment of glaucoma. The present invention further relates to the ph...
|
|
WO/2022/239868A1 |
The purpose of the present invention is to provide a method for producing retinal system cells or retinal tissue, in which method the proportion of non-target cells is reduced when pluripotent stem cell differentiation is induced. The me...
|
|
WO/2022/239863A1 |
The present invention addresses the problem of providing an antisense oligomer capable of treating Werner's syndrome without direct mutated gene repair, or a pharmacologically acceptable salt of the antisense oligomer. The present inve...
|
|
WO/2022/235786A1 |
Methods that increase bioavailability and/or efficacy of a therapeutic agent for treatment of an ocular surface disorder, cornea disorder, or anterior chamber disorder are provided. In particular, tear production is increased by administ...
|
|
WO/2022/234888A1 |
The present invention relates to a pharmaceutical composition for treating macular degeneration, containing an imidazoline derivative compound as an active ingredient. A composition containing an imidazoline derivative compound or a phar...
|
|
WO/2022/235906A1 |
Provided herein are solid forms of alpha-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl-(S)-
benzeneacetamide mono-tosylate salt ("Compound 1 mono-tosylate"), pharmaceutical compositions containing the solid forms, methods of produci...
|
|
WO/2022/235021A1 |
The present invention relates to a composition for prevention, alleviation, or treatment of dry eye syndrome or dry eye syndrome-related ophthalmologic diseases. In the present invention, the protein kinase A (PKA) cell signaling system ...
|
|
WO/2022/233318A1 |
Use of Cistanche tubulosa extract in preparation of a medicament for relieving dry eye symptoms. Said symptoms includ ocular burning, itching, stinging, excess watering, foreign body sensation, pain, redness, photophobia and blurred vision.
|
|
WO/2022/235780A1 |
Provided are recombinant adeno-associated virus (rAAV) virions, methods of treating an ocular condition, pharmaceutical compositions, and other compositions and methods, in which the rAAV virion comprises a polynucleotide encoding a neur...
|
|
WO/2022/229932A1 |
Provided are methods of treating, minimizing and/or inhibiting atrophy associated with retinal hypoxia, comprising administering a pharmaceutical composition comprising an HIF inhibitor to a subject having retinal hypoxia. The HIF inhibi...
|
|
WO/2022/232588A1 |
The present disclosure relates to a biodegradable ocular implant comprising a biodegradable polymer containing a compound such as Edonentan, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treatment of ocular...
|
|
WO/2022/229441A2 |
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to a composition comprising a specific combination of lipids and optionally one or more additives, and a method of preparing s...
|
|
WO/2022/232790A1 |
Provided are methods for treating an ocular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucl...
|
|
WO/2022/232257A1 |
Provided herein are compositions and methods for delivering a molecular therapeutic to the cochlea of a subject. The methods comprise administering an adeno-associated virus (AAV) to the cerebrospinal fluid of the subject. The AAVs encod...
|
|
WO/2022/230977A1 |
The present invention provides: a graft material of retinal pigment epithelial cells, which can be prepared within a short period of time and at low cost and can be controlled easily at a site at which the graft material is transplanted ...
|
|
WO/2022/228546A1 |
The present application relates to a method and pharmaceutical composition for treating myopia. The pharmaceutical composition or the method of the present application can effectively prevent and control myopia, is safe and has no obviou...
|
|
WO/2022/232597A1 |
The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, or a pharmaceutically acceptable salt thereof, for treating patients suffering from diab...
|
|
WO/2022/229787A1 |
The invention relates to a biocompatible product having a crosslinked matrix, in which a polysaccharide is co-crosslinked with chitosan, chitosan derivative, or chitosan salt, said matrix further comprising a divalent zinc cation.
|
|
WO/2022/232001A1 |
The present invention provides compositions, e.g., pharmaceutical compositions, which include a recombinant adeno-associated viral (AAV) expression construct, AAV vectors, AAV particles, and methods of treating a subject having a degener...
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/232249A1 |
The present disclosure relates to methods for regulating cholesterol efflux in retinal pigment epithelium cells and treating or preventing a neurodegenerative disease or disorder (e.g., macular degeneration).
|
|
WO/2022/225476A1 |
The present invention relates to injectable viscoelastic formulations which are developed by means of synergistic effect of hyaluronic acid (HA), vitamins, minerals, antioxidants and osmoprotectants, and which can be used in intraarticul...
|
|
WO/2022/225422A1 |
The present invention relates to a compound of formula (I): where Z is (II) in which R1 and R2 are identical or different and are hydrogen or a lower alkyl chain having up to 4 carbon atoms or a pharmaceutically acceptable salt thereof. ...
|
|
WO/2022/226347A1 |
Provided herein are pharmaceutical compositions and related methods for treating ophthalmic diseases. The method entails administering to the patient an effective amount of a CSF1R inhibitor, such as an anti-CSF1R antibody. The methods a...
|
|
WO/2022/222869A1 |
The present invention relates to a recombinant adeno-associated virus (AAV) and an application thereof. The present invention further relates to an AAV purification method and a purified AAV obtained thereby. The AAV in the present inven...
|
|
WO/2022/226187A1 |
This disclosure provides a method of stabilizing the interaction of a Retinoic Acid Receptor- alpha (RARα) and a corepressor, Nuclear Receptor Corepressor 1 (NCoRl) by contacting the RARa with an amount of a Chaperone Mediated Autophagy...
|
